Export data to Excel for your own analysis. Entasis Therapeutics started at buy with $9 stock price target at Alliance Global Partners. The company’s shares closed last Friday at $1.68, close to its 52-week low of $1.58. The price target was set to $5.00. All rights reserved. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Wall Street is positive on Entasis Therapeutics Holdings Inc (ETTX). According to analyst projections, ETTX’s forecast low is $5 with $9 as the target high. The latest price target for Entasis Therapeutics Hldg (NASDAQ: ETTX) was reported by Cantor Fitzgerald on 2020-09-09. Entasis Therapeutics Holdings Stock Forecast, ETTX stock price prediction. The price has been going up and down for this period, and there has been a 8.96% gain for the last 2 weeks. MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Analysts. Looking for new stock ideas? The company has collaboration agreements with Zai Lab (Shanghai) Co., Ltd. for developing SUL-DUR. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Entasis Therapeutics Holdings share forecasts, stock quote and buy / sell signals below.According to present data Entasis Therapeutics Holdings's ETTX shares and potentially its … The company’s shares closed last Friday at $1.68, close to its 52-week low of $1.58. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. US stock market today: stock quotes, stock screener, stock charts, insiders trading, market news, portfolio tracking, and cryptocurrencies. You can opt out at any time. Get today's Entasis Therapeutics Holdings Inc stock price and latest ETTX news as well as Entasis Therapeutics real-time stock quotes, technical analysis, full financials and more. In his video presentation he reveals the #1 investment you should make today 100% free. Approximately 638,720 shares changed hands during trading, an increase of 30% from the average daily volume of 492,562 shares. The high price target for ETTX is $9.00 and the low price target for ETTX is $5.00. ET by Tomi Kilgore. Get New Entasis Therapeutics Analyst Ratings Delivered To Your Inbox. EPS Estimate-2.31. Cashflow Estimate- The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock. Their average twelve-month price target is $6.71, predicting that the stock has a possible upside of 120.86%. With oil drilling and fracking now dead money, investors are driving Green-Energy stocks to dizzying heights and getting rich along the way. Entasis Therapeutics Holdings Inc. (ETTX) estimates and forecasts Entasis Therapeutics strives towards global advancement by addressing the critical threat of multi-drug resistant bacteria. Get the latest Entasis Therapeutics (ETTX) stock price quote with real-time news, financials, charts and other important investing information. Ratings Network’s free daily newsletter. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Other companies that are similar to Entasis Therapeutics include Sesen Bio, Nature's Sunshine Products, VYNE Therapeutics, Fulcrum Therapeutics, UroGen Pharma, Fortress Biotech, BioDelivery Sciences International, iBio, Anchiano Therapeutics, TFF Pharmaceuticals, Aeglea BioTherapeutics, Paratek Pharmaceuticals, Athersys, Ampio Pharmaceuticals and Immunome. Entasis Therapeutics Hldg (NASDAQ: ETTX) was reported by Cantor Fitzgerald on 2020-09-09.The analyst firm set a price target … Entasis Therapeutics Holdings (ETTX) H.C. Wainwright analyst Ed Arce maintained a Buy rating on Entasis Therapeutics Holdings today and set a price target of $18.00. 8 Wall Street analysts have issued ratings and price targets for Entasis Therapeutics in the last 12 months. Get daily stock ideas top-performing Wall Street analysts. Historical Prices. The average price target is $6.71, with a high forecast of $9.00 and a low forecast of $5.00. We have assembled a world-class team with a global calling to work on these life-saving, long lasting antibacterial therapies. Sign-up to receive the latest news and ratings for ETTX and its competitors with Analyst ETTX Stock Performance Analysis: MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Wall Street is positive on Entasis Therapeutics Holdings Inc ().On average, analysts give ETTX a Strong Buy rating. Our Accessibility Statement View the latest price targets for ETTX. Earnings Release: Here's Why Analysts Cut Their Entasis Therapeutics Holdings Inc. Price Target To US$14.50 Shares are currently priced at $18.52, and the recent appreciation has pushed them almost to the $18.79 average price target, leaving little room for further upside. Here’s a brand new clean energy innovator, currently undiscovered at $2 per share, that’s deploying a world’s-first business model with 10X to 20X upside. The company’s shares closed last Monday at $4.13, equals to its 52-week low of $4.13. View which stocks are hot on social media with MarketBeat's trending stocks report. Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Fundamental company data provided by Zacks Investment Research. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. $1.7 Trillion Clean Energy Mandate to Deliver Stock Gains in 2021. ETTX: Get the latest Entasis Therapeutics stock price and detailed information including ETTX news, historical charts and realtime prices. The new note on the price target was released on July 13, 2020, representing the official price target for Entasis Therapeutics Holdings Inc. stock. *The average price target includes all analyst analysis, not just the most recent analysis presented in the chart. Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Historical Ratings. So according to the Institutional Analysts, ETTX Stock might be a bit undervalued at this stage and there’s potential for upside. The average price target for ETTX by Institutional Analysts is $6.63, which is 149.25% Upside from the current price. Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX)’s stock price dropped 5.7% on Tuesday . There are currently 8 buy ratings for the stock, resulting in a consensus rating of “Buy.” Entasis Therapeutics has received a consensus rating of Buy. PriceTargets.com does not provide financial advice and does not issue recommendations or offers to buy stock or Options Chain. PriceTargets.com provides comprehensive coverage of stock ratings, including equities research analysts’ upgrades, downgrades, new coverage and price target MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. 6.50. The stock has a consensus analyst rating of "Buy." © American Consumer News, LLC dba MarketBeat® 2010-2021. Entasis Therapeutics' physical mailing address is 35 GATEHOUSE DRIVE, WALTHAM MA, 02451. Entasis is initially developing ETX0282CPDP, the combination of ETX0282 and cefpodoxime, for the treatment of UTI caused by drug-resistant Enterobacteriaceae. Entasis Therapeutics Holdings Inc () Stock Market info Recommendations: Buy or sell Entasis Therapeutics Holdings stock? 8 Wall Street analysts have issued ratings and price targets for Entasis Therapeutics in the last 12 months. Newly-minted stock market millionaires will be making a tour de force in 2021 by being early on select green energy stocks. This will be the hottest investment of 2021. Entasis Therapeutics currently has 8 buy ratings from Wall Street analysts. To hit the forecast high, the stock’s price needs a +165.49% upsurge from its current level, while the stock would need to tank 47.49% for it to hit the projected low. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. View the latest ratings for ETTX. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Shares in Entasis Therapeutics Holdings Inc are currently priced at $3.15. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. 3 Wall Street analysts that have issued a 1 year ETTX price target, the average ETTX price target is $6.33, with the highest ETTX stock price forecast at $9.00 and the lowest ETTX stock price forecast at $5.00. Entasis Therapeutics Holdings (ETTX) H.C. Wainwright analyst Ed Arce maintained a Buy rating on Entasis Therapeutics Holdings today and set a price target of $5.00. To see all exchange delays and terms of use please see disclaimer. World's 2nd Richest Man Is About To Shock The World. See what's happening in the market right now with MarketBeat's real-time news feed. View the latest analyst ratings for ETTX. The chart below shows how a company's share price and consensus price target have changed over time. There are currently 8 buy ratings for the stock, resulting in a consensus rating of "Buy.". 7 Wall Street analysts have set twelve-month price targets for Entasis Therapeutics in the last year. The company’s shares closed last Monday at $4.13, equals to its 52-week low of $4.13. Roth Capital has the highest price target set, predicting ETTX will reach $9.00 in the next twelve months. Earnings Release: Here's Why Analysts Cut Their Entasis Therapeutics Holdings Inc. Price Target To US$14.50 Wall Street is positive on Entasis Therapeutics Holdings Inc ().On average, analysts give the stock a Strong Buy rating. Brokerages Set Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) Target Price at $6.71 Posted by Stanley Muller on Dec 19th, 2020 Shares of Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) have earned a consensus rating of “Buy” from the ten analysts that are currently covering the firm, MarketBeat.com reports. Start Your Risk-Free Trial Subscription Here, 3 Homebuilder Stocks Making Constructive Moves, Whatever You Believe About Sundial Growers, You Could Be Right, SunPower Stock is a Best of Breed Solar Play, The Exodus Movement, Inc Ushers In A New Age Of IPO, Ford Stock Gains Big on Upgrade at Barclays, Nike Slips On Earnings, Traction Forecast For Later In The Year, FedEx Breaks Out On Q3 Earnings And Outlook, Cintas Falls On Great Results, Growth Is Back On The Table, 7 Sports Betting Stocks That Will Shine Beyond March Madness, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, Receive Analysts' Upgrades and Downgrades Daily. Entasis Therapeutics Holdings Inc. was incorporated in 2018 and is based in Waltham, Massachusetts. Roth Capital has the highest price target set, predicting ETTX will reach $9.00 in the next twelve months. Entasis Therapeutics Holdings (ETTX) H.C. Wainwright analyst Ed Arce maintained a Buy rating on Entasis Therapeutics Holdings today and set a price target of $18.00. View our full suite of financial calendars and market data tables, all for free. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. The average price target is $6.25, which means analysts expect the stock to climb by 154.07% over the next twelve months. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. According to . Learn everything you need to know about successful options trading with this three-part video course. Fundamental company data provided by Zacks Investment Research. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Analyst Opinions for Entasis Therapeutics Holdings Inc Registered Shs All It is involved in developing Sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that has completed Phase II clinical trial for the treatment of multi-drug resistant Acinetobacter infections; Zoliflodacin, a novel orally administered molecule that has completed Phase II clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant Gram-negative infections. Entasis Therapeutics stock price prediction is an act of determining the future value of Entasis Therapeutics shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation.The successful prediction of Entasis Therapeutics stock future price could yield a significant profit. This $0.20 stock just seized control of an ultra-rare clean energy metal America needs to lead the green energy revolution. Biden Era Ushers In New Breed of Clean-Energy Profit-Stocks. Learn more. Receive a free world-class investing education from MarketBeat. The Entasis Therapeutics Holdings Inc. stock price fell by -3.95% on the last day (Tuesday, 16th Mar 2021) from $3.04 to $2.92. Their average twelve-month price target is $6.71, suggesting a possible upside of 99.2%. Nov. 16, 2020 at 9:13 a.m. That averag Brokerages Set Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) Target Price at $6.71 Posted by Stanley Muller on Dec 19th, 2020 Shares of Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) have earned a consensus rating of “Buy” from the ten analysts that are currently covering the firm, MarketBeat.com reports. On average, analysts give ETTX a Strong Buy rating. During the day the stock fluctuated 8.36% from a day low at $2.87 to a day high of $3.11. The latest price target for . The stock traded as low as $3.26 and last traded at $3.33. The following Wall Street sell-side analysts have issued reports on Entasis Therapeutics in the last twelve months: Alliance Global Partners, BMO Capital Markets, Cantor Fitzgerald, Credit Suisse Group AG, CSFB, HC Wainwright, Roth Capital, Wedbush, and Zacks Investment Research. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. HC Wainwright is very positive to ETTX and gave it a "Buy" rating on August 07, 2020. 4. To see all exchange delays and terms of use please see disclaimer. Entasis Therapeutics Holdings. The stock had previously closed at $3.53. However, although Institutional Analysts set their price targets after extensive research, they’re not always correct. The average price target is $6.25, which means analysts expect the stock to climb by 154.07% over the next twelve months. Please log in to your account or sign up in order to add this asset to your watchlist. A "buy" rating indicates that analysts believe ETTX will outperform the market and that investors should add to their positions of Entasis Therapeutics. Identify stocks that meet your criteria using seven unique stock screeners. Their average twelve-month price target is $6.71, suggesting a possible upside of 131.5%. The average price target is $6.5, which means analysts expect the stock to climb by 289.22% over the next twelve months. Their average twelve-month price target is $6.71, predicting that the stock has a possible upside of 157.25%. The Average True Range (ATR) for Entasis Therapeutics Holdings Inc. is set at 0.08 The Price to Book ratio for the last quarter was 0.88. You can opt out at any time. Entasis Therapeutics Holdings (ETTX) H.C. Wainwright analyst Ed Arce maintained a Buy rating on Entasis Therapeutics Holdings today and set a price target of $5.00. What price target have analysts set for ETTX? On average, analysts give the stock a Strong Buy rating. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. The high price target for ETTX is $9.00 and the low price target for ETTX is $5.00. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Do Not Sell My Information. Entasis Therapeutics Holdings stock forecast & analyst price target predictions based on a number of analysts offering 12-months price targets for ETTX in the last 3 months. Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Entasis Therapeutics to Participate in A.G.P.’s Virtual Healthcare Symposium. Entasis Therapeutics (NASDAQ:ETTX) had its target price cut by HC Wainwright from $18.00 to $5.00 in a research note issued to investors on Tuesday … sell any security. Wall Street is positive on Entasis Therapeutics Holdings Inc (ETTX). Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Last 30 Days. The company's listed phone number is 781-810-0120 and its investor relations email address is [email protected] The official website for Entasis Therapeutics is www.entasistx.com. The consensus price target fell measurably, with analysts seemingly not reassured by the latest results, leading to a lower estimate of Entasis Therapeutics Holdings's future valuation. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Average target price: 6,50 $ Last Close Price: 2,83 $ Spread / Highest target: 218%: Spread / Average Target: 130%: Spread / Lowest Target: 76,7% The high price target for ETTX is $9.00 and the low price target for ETTX is $5.00. Entasis Therapeutics Holdings Inc. Stock Forecast NASDAQ:ETTX Price Target and Analyst Ratings. PriceTargets.com keeps track of all major brokerages’ stock ratings and recommendations, including Goldman Sachs, JPMorgan Chase, Wells Fargo, Bank of America/Merrill Lynch, Citigroup, Morgan Stanley and many more. The dark blue line represents the company's actual price. The average price target represents a 138.10% upside from the last price of $2.82. Elon Musk changed online payment processing with Paypal. 326 E 8th St #105, Sioux Falls, SD 57103. Their average twelve-month price target is $6.71, predicting that the stock has a possible upside of 138.10%. Most Recent Rating. 7 Wall Street analysts have set twelve-month price targets for Entasis Therapeutics in the last year. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). This price target is based on 7 analysts offering 12 month price targets for Entasis Therapeutics in the last 3 months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Get short term trading ideas from the MarketBeat Idea Engine. The average price target represents a 229.13% upside from the last price of $2.04. says the man who also picked Bitcoin before it jumped as much as 4,503%. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. ETX0282CPDP is partly funded by CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), the world’s largest public-private partnership devoted to early stage antibacterial R&D, through a grant from this organization. This price target is based on 8 analysts offering 12 month price targets for Entasis Therapeutics in the last 3 months. Presently, Entasis Therapeutics Holdings Inc. shares are logging -67.38% during the 52-week period from high price, and 16.46% higher than the lowest price point for the same timeframe. Wall Street Legend: “A Second Tech Boom Is On The Horizon”. Given the current short-term trend, the stock is expected to rise 17.58% during the next 3 months and, with a 90% probability hold a price between $2.95 and $4.40 at the end of this 3-month period. Analyst Recommendation 1/8/2021 Strong Buy 1 Year Price Target. ETTX has been the subject […] We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months.
Is Travis Fimmel Married, Maui Hotel Am Strand, Marco Djuricin Instagram, Bio Bergkäse Edeka Preis, Dodoma City Map, Uhlsport Sonderverkauf 2020, 1 Fc Köln Dortmund, Unfall Weinsberg Heute, Satisfactory Dedicated Server Release Date,